All In Biotech

Drug Trial Radar · NCT07515209

A Clinical Study of HH-006 in Untreated Chronic Hepatitis B Virus Infected Patients

A Randomized, Double-blind, Placebo-controlled Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Antiviral Activity of Multiple Doses of HH-006 Injection in Untreated Chronic Hepatitis B Virus Infected Individuals

Last checked: Nov 19, 2026Latest source record: Apr 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

36

Actual

Start

Dec 20, 2024

Primary completion

Dec 15, 2025

Study completion Dec 15, 2025

Sponsor

Lead sponsor
Huahui HealthIndustry
Sponsor type
Industry
First posted
Apr 7, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, placebo-controlled Phase I dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and antiviral activity of multiple ascending doses (120 mg, 240 mg, 480 mg SC, QW×5) of HH-006 in untreated chronic HBV patients. Each cohort includes 12 participants (9 active, 3 placebo), with dose progression approved by a Safety Review Committee. Participants are monitored through 24 weeks post-dose. The study design allows for adjustments based on emerging data.

Conditions

  • Chronic Hepatitis B Virus Infection

Interventions

  • HH-006Biological

    120 mg, 240 mg, 480 mg subcutaneous QW, 5 doses

  • 0.9% normal salineDrug

    1 mL, 2 mL, 4 mL subcutaneous QW, 5 doses

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of adverse events (AEs) and serious adverse events (SAEs)Time frame: up to 24 weeks follow-up
  2. Clinically significant abnormalitiesTime frame: up to 24 weeks follow-up

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • NanFang Hospital of Southern Medical University

    Guangzhou, Guangdong, China

  • The Affiliated Panyu Central Hospital of Guangzhou Medical University

    Guangzhou, Guangdong, China

  • The Eighth Affiliated Hospital of Guangzhou Medical University

    Guangzhou, Guangdong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.